Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
Conditions
Interventions
Pembrolizumab
Epacadostat
+2 more
Locations
140
United States
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
Scottsdale Healthcare
Scottsdale, Arizona, United States
Arizona Oncology Associates PC- HOPE
Tucson, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center
Orange, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
December 7, 2017
Primary Completion Date
August 22, 2018
Completion Date
June 4, 2025
Last Updated
July 29, 2025
NCT07117227
NCT07369505
NCT07175480
NCT06642220
NCT06916624
NCT05824975
Lead Sponsor
Incyte Corporation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions